m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05730
 [1]
m6A modification NEAT1 NEAT1 YTHDC1 : m6A sites Direct Enhancement Non-coding RNA NEAT1 KLF4  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator YTH domain-containing protein 1 (YTHDC1) READER
 Regulator Info 
m6A Target Nuclear paraspeckle assembly transcript 1 (NEAT1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Nuclear paraspeckle assembly transcript 1 (NEAT1) LncRNA View Details
Regulated Target Krueppel-like factor 4 (KLF4) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary Exercise Mitigates Endothelial Pyroptosis and Atherosclerosis by Downregulating Nuclear paraspeckle assembly transcript 1 (NEAT1) Through N6-Methyladenosine Modifications. Exercise induced a significant downregulation of m6A modification and METTL14, which binds to the m6A sites of NEAT1 and promotes NEAT1 expression through subsequent YTHDC1 (YTH domain-containing 1) recognition to promote endothelial pyroptosis. NEAT1 induces endothelial pyroptosis by binding Krueppel-like factor 4 (KLF4) to promote the transcriptional activation of the key pyroptotic protein NLRP3.
Responsed Disease Coronary atherosclerosis ICD-11: BA52.0
 Disease Info 
Cell Process Pyroptosis
In-vitro Model
 HUVECs (Human Umbilical Vein Endothelial Cells)
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Krueppel-like factor 4 (KLF4) 1 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name APTO-253 Phase 1 [2]
MOA Inhibitor
External Link
CID: 11960271
TTD: D07TRP
References
Ref 1 Exercise Mitigates Endothelial Pyroptosis and Atherosclerosis by Downregulating NEAT1 Through N6-Methyladenosine Modifications. Arterioscler Thromb Vasc Biol. 2023 Jun;43(6):910-926. doi: 10.1161/ATVBAHA.123.319251. Epub 2023 Apr 20.
Ref 2 Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2015 Oct;33(5):1086-92. doi: 10.1007/s10637-015-0273-z. Epub 2015 Aug 14.